© Globe Newswire
12.01.2026
MBRX
LISTED
NASDAQ
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
News Preview
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
CRSP
LISTED
NASDAQ
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
News Preview
-2026 is poised to be a data- and milestone-rich year across the portfolio-...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
ABBV
LISTED
EURONEXT
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
News Preview
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancersNORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC14...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
12.01.2026
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
News Preview
Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
12.01.2026
XENE
LISTED
NASDAQ
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
News Preview
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company’s Phase...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
IRON
LISTED
NASDAQ
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
News Preview
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline progress and strategic priorities for 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
DWTX
LISTED
NASDAQ
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
News Preview
ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to a...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
ALHC
LISTED
NASDAQ
Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026
News Preview
ORANGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), an award-winning Medicare Advantage (MA) company, today announced Jan. 1 health plan membership of approximately 275,300, representing 31% year-over-year growth following a strong annual enrollment period (AEP). Since its IPO in 2021, the company has achi...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
CLOV
LISTED
NASDAQ
Counterpart Health 2025 Results: How Better Clinical Decisions at Scale Improve Outcomes, Quality, and Cost
News Preview
Counterpart Health 2025 Results: How Better Clinical Decisions at Scale Improve Outcomes, Quality, and Cost...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
WGS
LISTED
NASDAQ
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2025.
“In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
DXCM
LISTED
NASDAQ
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
News Preview
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. Inter...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
NUVB
LISTED
NYSE
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
News Preview
Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company wo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.01.2026
BBNX
LISTED
NASDAQ
Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – BBNX
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to in...
Themefolio
Profiler
Peergroup
© Newsfile
12.01.2026
PMED
LISTED
CSE
Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare
News Preview
Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), excited to announce its proposed name change to QScreen AI Inc., with a new ticker symbol QAI, subject to regulatory approval. This strategic rebranding underscores the Company's evolution into a...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
SLDB
LISTED
XNMS
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
News Preview
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
BLLN
LISTED
NASDAQ
BillionToOne Provides Guidance for 2026
News Preview
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
MXCT
LISTED
NASDAQ
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
News Preview
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth q...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
CDNA
LISTED
NASDAQ
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
NEO
LISTED
NASDAQ
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.
Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
For the fourth quar...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
DTIL
LISTED
NASDAQ
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
News Preview
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clin...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
NCEL
LISTED
NASDAQ
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
News Preview
ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
BKD
LISTED
NYSE
Brookdale Reports December 2025 Occupancy
News Preview
Strong month-end occupancy provides a solid entry point and momentum for 2026BRENTWOOD, Tenn., Jan. 12, 2026 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its occupancy for December 2025.Fourth Quarter and December 2025 Occupancy ObservationsFourth quarter occupancy results:Consolidated weighted average occupancy of 82.5%...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
KPTI
LISTED
NASDAQ
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
News Preview
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –– Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 –– Preliminary Unaudited Full Year 2025 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $115 Million, Re...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
News Preview
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in ObesitySAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focu...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
CTSO
LISTED
NASDAQ
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
News Preview
Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75%DrugSorb®-ATR De Novo Pre-Submission Meeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-202...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
WAY
LISTED
NASDAQ
Waystar Introduces Agentic AI to Advance Toward the Autonomous Revenue Cycle
News Preview
Extends the impact of Waystar AltitudeAI, which has prevented $15.5 billion in denials in under one yearLeverages a unique combination of proprietary data from more than 7.5 billion annual transactions and one in three U.S. hospital dischargesLEHI, Utah, and LOUISVILLE, Ky., Jan. 12, 2026 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leadin...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
BSX
LISTED
NYSE
Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation
News Preview
Acquisition to expand urology offerings for people living with overactive bladderMARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
CNTB
LISTED
NASDAQ
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
News Preview
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
GERN
LISTED
NASDAQ
Geron Corporation Provides 2026 Financial Guidance
News Preview
2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
RKDA
LISTED
NASDAQ
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds
News Preview
DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally iss...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
CVRX
LISTED
NASDAQ
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
News Preview
MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2025 revenu...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
ERAS
LISTED
NASDAQ
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
News Preview
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
COGT
LISTED
NASDAQ
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
News Preview
WALTHAM, Mass. and BOULDER, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company’s key 2026 milestones ahead of its presentation at J.P. Morgan’s 44th annual healthcare conference. “2025 wa...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
CABA
LISTED
NASDAQ
Cabaletta Bio Announces 2026 Strategic Priorities
News Preview
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose ...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS12 January 2026 at 15:00 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
MDXH
LISTED
NASDAQ
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
News Preview
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences...
Themefolio
Profiler
Peergroup
© Newsfile
12.01.2026
TLT
LISTED
TSX
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
News Preview
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ with or without papillary disease (±Ta/T1).Combination therapy ai...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
TLSI
LISTED
NASDAQ
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
News Preview
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year end...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
UNH
LISTED
NYSE
New Independent Studies: Medicare Advantage Delivers Greater Value to the Federal Government and Beneficiaries than Traditional Medicare
News Preview
UnitedHealth Group today announced the release of two new, independent commissioned actuarial studies.
The findings, from the independent actuarial and research firm Milliman, using estimates of 2025 costs, summarize the value of Medicare Advantage (MA) both to the government and beneficiaries. Milliman found that:
MA costs the federal govern...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
BCYC
LISTED
NASDAQ
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
News Preview
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today highlights 2025 accomplishments and strategic priorities for 2026.
"In 2025, we remained steadfast in our goal of helping patients live longer and live...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
NGNE
LISTED
NASDAQ
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for multiple value-creating catalysts anticipated in 2026....
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
ANTX
LISTED
NASDAQ
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
News Preview
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration has cleared Oregon Health & Science University’s (OHSU) Investigational New Drug (IND) application to proceed with an IIT that will...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
TEM
LISTED
NASDAQ
Northwestern Medicine Selects Tempus to Expand Genomic Testing
News Preview
Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
SRRK
LISTED
NASDAQ
Scholar Rock Highlights 2026 Strategic Priorities
News Preview
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corpor...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
45280
LISTED
XJPX
Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Ono Pharmaceutical Co., Ltd. (TSE:4528) today announced that Toichi Takino, President and COO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.
A live webcast of the event will be available here and accessible for 30 days following the presentation.
About Ono P...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
NVCR
LISTED
NASDAQ
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
News Preview
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFiel...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
IONS
LISTED
NASDAQ
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 8:15am PT; the presentation is available today on the Ioni...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
HSIC
LISTED
NASDAQ
Henry Schein Names Frederick M. Lowery as Chief Executive Officer
News Preview
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer (“CEO”), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergm...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The trial met its primary endpoint, demonstr...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
NUVL
LISTED
NASDAQ
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
News Preview
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026Submission for potential indication expansion of zidesamtinib in T...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
ADPT
LISTED
NASDAQ
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
News Preview
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
XOMA
LISTED
NASDAQ
XOMA Royalty Announces CFO Transition
News Preview
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
WVE
LISTED
NASDAQ
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
News Preview
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
IRTC
LISTED
NASDAQ
iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conferenc...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
RARE
LISTED
NASDAQ
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
News Preview
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
KNSA
LISTED
NASDAQ
Kiniksa Pharmaceuticals Provides Corporate Update
News Preview
– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $17...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
ZURA
LISTED
NASDAQ
Zura Bio Reports Business Updates and Outlook for 2026
News Preview
Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026.
“We are excited to enter 2026, as we get...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
SMMT
LISTED
NASDAQ
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2026
KIDS
LISTED
NASDAQ
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
News Preview
Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior yearInitiates guidance for record Adjusted EBITDA in 2026...
Themefolio
Profiler
Peergroup
© PR Newswire
12.01.2026
WST
LISTED
NYSE
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
News Preview
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
